Elucid offers PlaqueIQ™, the first and only FDA-cleared, non-invasive plaque analysis software based on histopathology-validated algorithms. Unlike traditional CTA methods, PlaqueIQ provides detailed, lesion-level insights into plaque composition—such as lipid-rich necrotic core and calcified areas—using CT Virtual Histology™. Designed to support personalized cardiovascular treatment decisions, the software delivers results via interactive web tools and PACS-ready reports. Elucid is also developing Plaque-Derived FFRCT, which integrates plaque biology into functional assessments, with FDA submission planned for late 2025.